1Ascioglu S,Rex JH,de Pauw B,et al.Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants:an international consensus[J].Clin Infect Dis,2002,34(1):7-14.
2Marr KA,Carter RA,Boeckh M,et al.Invasive aspergillosis in allogeneic stem cell transplant recipients:changes in epidemiology and risk factors[J].Blood,2002,100(13):4358-4366.
3Hof H.Developments in the epidemiolgy of invasive fungal infections-implications for the empiric and targeted antifungal therapy[J].Mycoses,2008,51(Suppl 1):1-6.
4Pappas PG,Rex JH,Sobel JD,et al.Guideline for treatment of eandidiasis[J].Clin Infect Dis,2004,38(2):161-189.
6Hebrecht R,Denning DW,Patterson TF,et al.Voriconazole Versus amphotericin B for primary therapy of invasive aspergillosis[J].N Engl J Med,2002,347(6):408-415.
7Sambatakou H,Dupont B,Lode H,et al.Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis[J].Am J Med,2006,119(6):527.el7-24.
同被引文献13
1Patterson TF,K irkpatrick WR,W h ite M. Invasive aspergillosis D isease spectrum,treatm ent practices,and outcom es.I3 aspergillusstudy group[J].{H}MEDICINE,2000,(04):250-260.
2Wiederhold NP,Lewis JS. The echinocandin micafungin:a review of the pharmacology,spectrum of activity,clinical efficacy and safety[J].{H}EXPERT OPINION ON PHARMACOTHERAPY,2007,(08):1155-1166.
